{"id": "article-17300_0", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Continuing Education Activity", "content": "Human immunodeficiency virus infection is a significant health problem worldwide. Advances in treatment have made this disease not only manageable but have also dramatically decreased the incidence of opportunistic infections and decreased progression to acquired immunodeficiency syndrome. Practitioners should utilize current guidelines for treatment. This activity describes these guidelines and highlights the role of interprofessional teams in treating this complex disorder.", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Continuing Education Activity. Human immunodeficiency virus infection is a significant health problem worldwide. Advances in treatment have made this disease not only manageable but have also dramatically decreased the incidence of opportunistic infections and decreased progression to acquired immunodeficiency syndrome. Practitioners should utilize current guidelines for treatment. This activity describes these guidelines and highlights the role of interprofessional teams in treating this complex disorder."}
{"id": "article-17300_1", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Continuing Education Activity", "content": "Objectives: Describe how a patient with acute HIV infection might present, and the initial screening test that should be done. Identify when antiretroviral therapy should be initiated in patients with human immunodeficiency virus. Outline some common antiretroviral therapy regimens. Summarize collaboration with interprofessional team members to ensure that high risk patients are being educated about and offered pre-exposure HIV prophylaxis. Access free multiple choice questions on this topic.", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Continuing Education Activity. Objectives: Describe how a patient with acute HIV infection might present, and the initial screening test that should be done. Identify when antiretroviral therapy should be initiated in patients with human immunodeficiency virus. Outline some common antiretroviral therapy regimens. Summarize collaboration with interprofessional team members to ensure that high risk patients are being educated about and offered pre-exposure HIV prophylaxis. Access free multiple choice questions on this topic."}
{"id": "article-17300_2", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Introduction", "content": "Human immunodeficiency virus (HIV) infection has become a health problem worldwide. Advances in treatment have made this disease not only manageable but have also dramatically decreased the incidence of opportunistic infections and decreased progression to acquired immunodeficiency syndrome (AIDS). Current guidelines on HIV treatment are more aggressive on when to start treatment, given that recent studies have shown improved outcomes with earlier initiation of therapy.\u00a0In this review, we will focus on HIV antiretroviral therapy. [1] [2]", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Introduction. Human immunodeficiency virus (HIV) infection has become a health problem worldwide. Advances in treatment have made this disease not only manageable but have also dramatically decreased the incidence of opportunistic infections and decreased progression to acquired immunodeficiency syndrome (AIDS). Current guidelines on HIV treatment are more aggressive on when to start treatment, given that recent studies have shown improved outcomes with earlier initiation of therapy.\u00a0In this review, we will focus on HIV antiretroviral therapy. [1] [2]"}
{"id": "article-17300_3", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Etiology", "content": "HIV is an enveloped ribonucleic retrovirus, subgroup lentivirus. There are two species of HIV that cause human disease. HIV-1 has high virulence and infectivity and is prevalent worldwide, HIV-2 has lower virulence and infectivity and is more prevalent in West Africa.", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Etiology. HIV is an enveloped ribonucleic retrovirus, subgroup lentivirus. There are two species of HIV that cause human disease. HIV-1 has high virulence and infectivity and is prevalent worldwide, HIV-2 has lower virulence and infectivity and is more prevalent in West Africa."}
{"id": "article-17300_4", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Epidemiology", "content": "HIV prevalence has increased worldwide. This is related to an increased survival of HIV-infected individuals thanks to highly active antiretroviral therapy. The incidence of HIV has been declining and is expected to keep declining with increased awareness of the disease and the advent of\u00a0pre-exposure prophylaxis therapy.", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Epidemiology. HIV prevalence has increased worldwide. This is related to an increased survival of HIV-infected individuals thanks to highly active antiretroviral therapy. The incidence of HIV has been declining and is expected to keep declining with increased awareness of the disease and the advent of\u00a0pre-exposure prophylaxis therapy."}
{"id": "article-17300_5", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Pathophysiology", "content": "HIV transmission occurs through the exchange of bodily fluids. The most common route of transmission is sexual through the anogenital mucosa. It penetrates into the body by binding its\u00a0GP120 molecule to CD4 molecules on dendritic cells in the mucosa. After entering the body, the virus invades macrophages (by binding\u00a0GP120 to the chemokine receptor CCR5 as well as CD4) or T cell (by binding\u00a0GP120 to the chemokine receptor CXCR4 as well as CD4) depending on the virus. After penetrating the cell, viral RNA will get transcribed to DNA by the virus own Reverse transcriptase.\u00a0The DNA is then included into the host's DNA with the use of the virus Integrase enzyme. This DNA later transcribes into new RNA molecules that will be enveloped by proteins that have been cleaved into form by the HIV protease. These forms mature virions that later bud out of the cell and go to infect other cells. Highlighted in bold are those places where\u00a0HIV antiretroviral therapy\u00a0acts on different parts of the viral cycle. [3]", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Pathophysiology. HIV transmission occurs through the exchange of bodily fluids. The most common route of transmission is sexual through the anogenital mucosa. It penetrates into the body by binding its\u00a0GP120 molecule to CD4 molecules on dendritic cells in the mucosa. After entering the body, the virus invades macrophages (by binding\u00a0GP120 to the chemokine receptor CCR5 as well as CD4) or T cell (by binding\u00a0GP120 to the chemokine receptor CXCR4 as well as CD4) depending on the virus. After penetrating the cell, viral RNA will get transcribed to DNA by the virus own Reverse transcriptase.\u00a0The DNA is then included into the host's DNA with the use of the virus Integrase enzyme. This DNA later transcribes into new RNA molecules that will be enveloped by proteins that have been cleaved into form by the HIV protease. These forms mature virions that later bud out of the cell and go to infect other cells. Highlighted in bold are those places where\u00a0HIV antiretroviral therapy\u00a0acts on different parts of the viral cycle. [3]"}
{"id": "article-17300_6", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- History and Physical", "content": "Acute HIV infection may manifest as a mononucleosis-like syndrome with mainly nonspecific symptoms or be completely\u00a0asymptomatic.", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- History and Physical. Acute HIV infection may manifest as a mononucleosis-like syndrome with mainly nonspecific symptoms or be completely\u00a0asymptomatic."}
{"id": "article-17300_7", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- History and Physical", "content": "Chronic untreated infection progresses to CD-4 cell depletion and the development of acquired immunodeficiency syndrome with the appearance of different opportunistic infections and metabolic, cardiovascular, oncologic and neurocognitive comorbidities.", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- History and Physical. Chronic untreated infection progresses to CD-4 cell depletion and the development of acquired immunodeficiency syndrome with the appearance of different opportunistic infections and metabolic, cardiovascular, oncologic and neurocognitive comorbidities."}
{"id": "article-17300_8", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Evaluation", "content": "New more sensitive tests for HIV detection have been developed, and the diagnostic algorithm has been recently revised and updated. Initial diagnostic testing and screening should be done with antigen/antibody (4th gen) immunoassay that detects both HIV-1 and 2, as well as p24 antigen. This allows for earlier detection of infection by adding direct antigen testing to the initial screen (3rd generation immunoassays tested only for antibodies). A negative specimen does not require further testing. Patients with a positive test should be confirmed with an antibody immunoassay that differentiates HIV-1 from HIV-2 (as opposed to western blot). Positive tests define the diagnosis of HIV and subspecies. Patients that have a negative result or indeterminate in a confirmatory test should be tested with an HIV-1 NAT (nucleic acid testing). A positive test indicates acute HIV-1 infection. A negative test indicates a false positive result in initial testing and patient should be considered not infected. After confirmation of diagnosis and before initiation of treatment all patients should have a CD4 cell count, HIV RNA viral load, complete metabolic and blood count done, as well as genotypic resistance testing for the virus. [4]", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Evaluation. New more sensitive tests for HIV detection have been developed, and the diagnostic algorithm has been recently revised and updated. Initial diagnostic testing and screening should be done with antigen/antibody (4th gen) immunoassay that detects both HIV-1 and 2, as well as p24 antigen. This allows for earlier detection of infection by adding direct antigen testing to the initial screen (3rd generation immunoassays tested only for antibodies). A negative specimen does not require further testing. Patients with a positive test should be confirmed with an antibody immunoassay that differentiates HIV-1 from HIV-2 (as opposed to western blot). Positive tests define the diagnosis of HIV and subspecies. Patients that have a negative result or indeterminate in a confirmatory test should be tested with an HIV-1 NAT (nucleic acid testing). A positive test indicates acute HIV-1 infection. A negative test indicates a false positive result in initial testing and patient should be considered not infected. After confirmation of diagnosis and before initiation of treatment all patients should have a CD4 cell count, HIV RNA viral load, complete metabolic and blood count done, as well as genotypic resistance testing for the virus. [4]"}
{"id": "article-17300_9", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Treatment / Management", "content": "There are many different categories of\u00a0HIV antiretroviral therapy: Medications that prevent entry of the virus into the cell by inhibiting CCR5 or GP41 are called\u00a0fusion\u00a0or\u00a0entry inhibitors. Medications that prevent transcription of viral RNA into DNA are called\u00a0nucleoside reverse transcriptase inhibitors (NRTI)\u00a0and\u00a0non-nucleoside reverse transcriptase inhibitors (NNRTI). Medication that inhibits the integration of transcribed viral DNA into the host's DNA is called\u00a0integrase inhibitors. Finally, medications that prevent protein cleavage from forming a virion are called\u00a0protease inhibitors.", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Treatment / Management. There are many different categories of\u00a0HIV antiretroviral therapy: Medications that prevent entry of the virus into the cell by inhibiting CCR5 or GP41 are called\u00a0fusion\u00a0or\u00a0entry inhibitors. Medications that prevent transcription of viral RNA into DNA are called\u00a0nucleoside reverse transcriptase inhibitors (NRTI)\u00a0and\u00a0non-nucleoside reverse transcriptase inhibitors (NNRTI). Medication that inhibits the integration of transcribed viral DNA into the host's DNA is called\u00a0integrase inhibitors. Finally, medications that prevent protein cleavage from forming a virion are called\u00a0protease inhibitors."}
{"id": "article-17300_10", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Treatment / Management -- Who and How to treat?", "content": "Based on recent multicenter-multinational randomized controlled trials the latest guidelines indicate that\u00a0HIV antiretroviral therapy\u00a0should be initiated early in the disease process regardless of CD4 cell count in all adult and adolescent patients.\u00a0This strategy has been shown to decrease morbidity and mortality related to HIV infection as well as HIV transmission. [5] [6]", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Treatment / Management -- Who and How to treat? Based on recent multicenter-multinational randomized controlled trials the latest guidelines indicate that\u00a0HIV antiretroviral therapy\u00a0should be initiated early in the disease process regardless of CD4 cell count in all adult and adolescent patients.\u00a0This strategy has been shown to decrease morbidity and mortality related to HIV infection as well as HIV transmission. [5] [6]"}
{"id": "article-17300_11", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Treatment / Management -- Who and How to treat?", "content": "HIV antiretroviral therapy\u00a0should always be done with combination regimens. Initial treatment usually consists of two NRTIs (usually abacavir/lamivudine or tenofovir/emtricitabine) in combination with a third antiviral drug from one of the following classes: integrase inhibitor, NNRTI or protease inhibitor plus an enhancer (cobicistat or ritonavir). This is based on the proven efficacy of this regimen and more favorable side effect profile. Alternative treatments may be considered in special patients.", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Treatment / Management -- Who and How to treat? HIV antiretroviral therapy\u00a0should always be done with combination regimens. Initial treatment usually consists of two NRTIs (usually abacavir/lamivudine or tenofovir/emtricitabine) in combination with a third antiviral drug from one of the following classes: integrase inhibitor, NNRTI or protease inhibitor plus an enhancer (cobicistat or ritonavir). This is based on the proven efficacy of this regimen and more favorable side effect profile. Alternative treatments may be considered in special patients."}
{"id": "article-17300_12", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Treatment / Management -- Who and How to treat?", "content": "Recommended initial regimens include four integrase inhibitor-based regimens (Dolutegravir/Tenofovir Fumarate/Emcitrabine;\u00a0Raltegravir/Tenofovir Fumarate/Emcitrabine; Dolutegravir/abacavir/lamivudine (for HLA-B*5701 negative patients); Elitegravir-cobicistat/Tenofovir Fumarate/Emcitrabine, Elitegravir-cobicistat/Tenofovir Alafenamide/Emcitrabine)\u00a0and one protease inhibitor-based regimen (Darunavir-ritonavir/Tenofovir Fumarate/Emcitrabine). Listed integrase inhibitor-based regimens have high efficacy, safety, and tolerability, as well as low drug interactions for\u00a0Raltegravir/Tenofovir Fumarate/Emtricitabine.", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Treatment / Management -- Who and How to treat? Recommended initial regimens include four integrase inhibitor-based regimens (Dolutegravir/Tenofovir Fumarate/Emcitrabine;\u00a0Raltegravir/Tenofovir Fumarate/Emcitrabine; Dolutegravir/abacavir/lamivudine (for HLA-B*5701 negative patients); Elitegravir-cobicistat/Tenofovir Fumarate/Emcitrabine, Elitegravir-cobicistat/Tenofovir Alafenamide/Emcitrabine)\u00a0and one protease inhibitor-based regimen (Darunavir-ritonavir/Tenofovir Fumarate/Emcitrabine). Listed integrase inhibitor-based regimens have high efficacy, safety, and tolerability, as well as low drug interactions for\u00a0Raltegravir/Tenofovir Fumarate/Emtricitabine."}
{"id": "article-17300_13", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Treatment / Management -- Who and How to treat?", "content": "Although not as well tolerated, listed protease inhibitor regimen (Darunavir-ritonavir/Tenofovir Fumarate/Emcitrabine) is recommended for patients who are suspected will be relatively incompliant or patients with NRTI resistance, this is because of the high genetic barrier to resistance that protease inhibitors confer. Nevertheless, because it is somewhat\u00a0lower efficacy, this regimen should be avoided in individuals with CD4 count less than 200 or HIV RNA greater than 100000).", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Treatment / Management -- Who and How to treat? Although not as well tolerated, listed protease inhibitor regimen (Darunavir-ritonavir/Tenofovir Fumarate/Emcitrabine) is recommended for patients who are suspected will be relatively incompliant or patients with NRTI resistance, this is because of the high genetic barrier to resistance that protease inhibitors confer. Nevertheless, because it is somewhat\u00a0lower efficacy, this regimen should be avoided in individuals with CD4 count less than 200 or HIV RNA greater than 100000)."}
{"id": "article-17300_14", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Treatment / Management -- Who and How to treat?", "content": "Consideration should be taken to make treatment as comfortable as possible for the patient. Listed once a day regimens include\u00a0Dolutegravir/abacavir/lamivudine and Elvitegravir-Cobicistat/Tenofovir Fumarate/Emtricitabine. Other important considerations to take when starting\u00a0HIV antiretroviral therapy: In patients with CKD Elvitegravir-cobicistat/Tenofovir Fumarate/Emtricitabine (CrCl greater than 70), and Elvitegravir-cobicistat/Tenofovir Alafenamide/Emtricitabine\u00a0(CrCl greater than 30) should be avoided. In osteoporotic patients, regimens containing Tenofovir Fumarate should be avoided. Dolutegravir/Abacavir/Lamivudine is a good regimen option for these patients. For patients with HIV dementia and psychiatric illness, as well as patients on methadone, Efavirenz should be avoided. Dolutegravir is to be avoided on high cardiac risk patients. Dolutegravir, Efavirenz, Elvitegravir/cobicistat and protease inhibitors may cause or worsen dyslipidemias.", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Treatment / Management -- Who and How to treat? Consideration should be taken to make treatment as comfortable as possible for the patient. Listed once a day regimens include\u00a0Dolutegravir/abacavir/lamivudine and Elvitegravir-Cobicistat/Tenofovir Fumarate/Emtricitabine. Other important considerations to take when starting\u00a0HIV antiretroviral therapy: In patients with CKD Elvitegravir-cobicistat/Tenofovir Fumarate/Emtricitabine (CrCl greater than 70), and Elvitegravir-cobicistat/Tenofovir Alafenamide/Emtricitabine\u00a0(CrCl greater than 30) should be avoided. In osteoporotic patients, regimens containing Tenofovir Fumarate should be avoided. Dolutegravir/Abacavir/Lamivudine is a good regimen option for these patients. For patients with HIV dementia and psychiatric illness, as well as patients on methadone, Efavirenz should be avoided. Dolutegravir is to be avoided on high cardiac risk patients. Dolutegravir, Efavirenz, Elvitegravir/cobicistat and protease inhibitors may cause or worsen dyslipidemias."}
{"id": "article-17300_15", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Differential Diagnosis", "content": "Cancer Chemotherapy Common variable immunodeficiency (CVID) DiGeorge syndrome Hepatitis B Malnutrition Severe combined immunodeficiency (SCID) Steroid therapy Syphilis Wiskott-Aldrich syndrome Lyme disease", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Differential Diagnosis. Cancer Chemotherapy Common variable immunodeficiency (CVID) DiGeorge syndrome Hepatitis B Malnutrition Severe combined immunodeficiency (SCID) Steroid therapy Syphilis Wiskott-Aldrich syndrome Lyme disease"}
{"id": "article-17300_16", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Pearls and Other Issues", "content": "Pre-exposure prophylaxis has been introduced in those groups who\u00a0are at substantial risk of acquiring AIDS (e.g., MSM). It is an effective preventive tool for these groups, and it protects them from acquiring AIDS.", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Pearls and Other Issues. Pre-exposure prophylaxis has been introduced in those groups who\u00a0are at substantial risk of acquiring AIDS (e.g., MSM). It is an effective preventive tool for these groups, and it protects them from acquiring AIDS."}
{"id": "article-17300_17", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Enhancing Healthcare Team Outcomes", "content": "An evidence-based\u00a0approach to preexposure HIV prophylaxis", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Enhancing Healthcare Team Outcomes. An evidence-based\u00a0approach to preexposure HIV prophylaxis"}
{"id": "article-17300_18", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Enhancing Healthcare Team Outcomes", "content": "More evidence has accumulated that pre-exposure HIV prophylaxis may be a better and more effective way to treat patients at high risk for HIV. Healthcare workers should be aware of this regimen since it is cheaper, simpler and safer than the traditional HAART regimen. Once preexposure prophylaxis is initiated, the goal is to ensure compliance, side effects of the medications and educate the patient on lowering of high-risk behaviors. While short-term studies indicate that pre-exposure HIV prophylaxis does\u00a0work, more\u00a0long-term\u00a0studies are needed to determine if this also results in a lowering of HIV cases and slows down the HIV epidemic. [7] [8]", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Enhancing Healthcare Team Outcomes. More evidence has accumulated that pre-exposure HIV prophylaxis may be a better and more effective way to treat patients at high risk for HIV. Healthcare workers should be aware of this regimen since it is cheaper, simpler and safer than the traditional HAART regimen. Once preexposure prophylaxis is initiated, the goal is to ensure compliance, side effects of the medications and educate the patient on lowering of high-risk behaviors. While short-term studies indicate that pre-exposure HIV prophylaxis does\u00a0work, more\u00a0long-term\u00a0studies are needed to determine if this also results in a lowering of HIV cases and slows down the HIV epidemic. [7] [8]"}
{"id": "article-17300_19", "title": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Acquired Immune Deficiency Syndrome Antiretroviral Therapy -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}